T he use of cyclosporine as an immunosuppressive agent in solid organ and bone marrow transplantation has been associated with a significant improvement in graft and patient survival.' However, the introduction of cyclosporine has been associated with a significant increase in the incidence of posttransplant hypertension irrespective of the transplanted organ. Hypertension also occurs in patients who have not received transplants but are receiving cyclosporine for other clinical conditions thought to be immunologically mediated. 2 Several pathophysiological mechanisms have been proposed to explain the hypertensive effect of cyclosporine, including direct and sympathetically mediated vasoconstriction. 34 Some authors have speculated that renal vasoconstriction, with resultant extracellular volume expansion caused by retention of salt and water, provides the probable hypertensive mechanism.5 The genesis of the renal vasoconstriction remains as yet unclear, but cyclosporine has been shown to possess intrinsic vasoconstrictor properties6 and also to increase sensitivity to a number of vasoconstrictor substances in isolated blood vessels.7 Renal sympathoexcitation has been described in animals after acute infusions of cyclosporine.3'8 Recently, Scherrer et a14 measured muscle sympathetic nerve traffic in cardiac transplant recipients and patients with myasthenia gravis who were treated with cyclosporine. They found that sympathetic nerve firing was increased, leading the authors to conclude that cyclosporine-induced hypertension was mediated via the sympathetic nervous system. Conversely, Floras et a19 described the normalization of muscle sympathetic nerve activity in a patient with hepatic cirrhosis after liver transplantation who was receiving cyclosporine therapy.
The aim of our study, therefore, was to further evaluate a potential direct role for the sympathetic nervous system in the pathogenesis of cyclosporineinduced hypertension in cardiac transplant recipients. Two 
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CyA, cyclosporine A; E, enalapril; P, prazosin; N, nifedipine; Fr, frusemide; Fe, felodipine; M, metoprolol. Patients 15 and 16 underwent both norepinephrine kinetic study and microneurography, on separate occasions (at least 2 months apart). mitter overflow to plasma and an electrophysiological technique for determining multiunit sympathetic nerve firing in skeletal muscle. These measurements were performed in conjunction with a hemodynamic evaluation of the influence of cyclosporine on regional (renal and forearm) and total vascular resistance.
Methods

Experimental Subjects
Subjects comprised 20 cardiac transplant recipients (described in the Table) and 17 healthy control subjects. The mean age of the heart transplant recipients was 53 + 2 years, and the controls were aged 46±3 years. The transplant recipients were a mean of 49±2 weeks after transplant (range, 5 to 124 weeks). At the time of study, all transplant recipients were free from allograft rejection and symptoms of heart failure. They were selected consecutively, independent of their blood pressure status. All subjects were in sinus rhythm during their procedures, confirmed by continuous ECG monitoring in both study protocols. In transplant recipients receiving antihypertensive therapy (see the Table) , these medications (including diuretics) were withheld for 72 hours before study. Prednisolone (mean dose, 11.5±0.9 mg/d) and azathioprine (mean dose, 90±10 mg/d) were continued during this period. The healthy control subjects were recruited from the general community by advertisement and underwent thorough medical screening before participation. None of the control subjects were receiving any medications. Tea, coffee, and cigarettes were witheld for a minimum of 12 hours before testing in both transplant recipients and control subjects. Studies were performed in the morning after a standardized light breakfast.
All subjects gave written informed consent, and the study was approved by the Alfred Hospital Ethics Review Committee.
General Study Design
To investigate the potential influence of cyclosporine on the sympathetic nervous system, the study incorporated a biochemical assessment of whole-body and renal sympathetic function together with microneurography to test muscle sympathetic nerve activity. The effects of cyclosporine on hemodynamic variables (blood pressure, cardiac output, renal blood flow, and forearm blood flow) were also determined. These measurements were performed either as single observations (2 hours after dosing) or as multiple observations before and after cyclosporine dosing. When the effects of cyclosporine dosing were examined, transplant recipients received their usual cyclosporine dose (Table) determined previously by the Heart Replacement Service, Alfred Hospital, according to their usual clinical and biochemical protocol. Control subjects did not receive cyclosporine.
Experimental Procedures
Total and renal norepinephrine kinetics and renal blood flow. Measurement of whole-body and renal norepinephrine kinetics and renal blood flow was performed in 14 transplant recipients and 8 control subjects. Under local anesthetic, the brachial or radial artery was cannulated (3.0F, 5- Arterial samples were also drawn for determination of the hematocrit and the whole-blood cyclosporine level.
In five of the transplant recipients, hemodynamic measurements were made and arterial and renal venous samples were obtained both before their usual oral dose of cyclosporine and thereafter at 30-minute intervals for 2 hours, whereas in an additional three patients, the same protocol was followed without cyclosporine dosing, these patients serving as a control group for any random effects with time. In the six remaining transplant recipients, single observations were performed only at 2 hours after cyclosporine dosing. Study durations were restricted to a maximum observation period of 2 hours after cyclosporine dosing for the purposes of subject comfort and because of pharmacokinetic data" that suggest that whole-blood levels of cyclosporine reach their peak approximately 2 hours after oral administration in cardiac transplant recipients. Control subjects underwent arterial and renal venous sampling at only one time point.
The whole-body spillover rate of norepinephrine was calculated by the isotope dilution method developed in our laboratory.10 The spillover rate (plasma appearance rate) of norepinephrine is equivalent to the rate of infusion of tritiated norepinephrine (expressed as disintegrations per minute) divided by the specific activity of plasma norepinephrine (disintegrations per minute per picomole). Renal norepinephrine spillover rate12 was calculated according to the equation
Renal Norepinephrine Spillover Rate= [(Cv-Ca)+(CaxER)]XPF where Ca and Cv are the arterial and venous plasma concentrations of norepinephrine, respectively, ER is the fractional extraction of norepinephrine tracer across the kidney, and PF is the renal plasma flow (determined from the clearance and fractional renal extraction of PAH). Arterial levels of tritiated dihydroxyphenylglycol (3H-DHPG) were also determined. DHPG is the major intraneuronal metabolite of norepinephrine, and the level of 3H-DHPG is a reflection of the activity of the process for the reuptake of neuronally released norepinephrine. 13 The renal production of 3H-DHPG was determined as the product of the renal blood flow and the renal 3H-DHPG venoarterial difference. '4 Renal plasma flow was estimated from the wholebody clearance and renal extraction of PAH. The concentration of PAH in arterial and renal venous plasma was determined from standard optical density/ PAH concentration curves for each individual's plasma. The renal plasma flow was calculated by correcting the PAH clearance for the renal extraction of PAH. Renal plasma flow was converted to renal blood flow with the use of each subject's hematocrit. The renal vascular resistance was subsequently derived as the ratio of the mean arterial pressure to the renal blood flow.
Arterial and renal venous blood were also drawn for the determination of plasma renin activity. The renal secretion of renin was then calculated as the product of the renal plasma flow and the venoarterial difference in plasma renin activity.
Microneurography. Efferent sympathetic nerve activity in the peroneal nerve was recorded according to the technique of Valbo et a115 and as previously performed in our laboratory16 in six cardiac transplant recipients and nine control subjects. Two of these subjects (patients 15 and 16, Table) also participated in the protocol described above, although the two studies were separated by an interval of at least 2 months.
A sterile tungsten microelectrode with a noninsulated tip 1 mm in diameter (Titronics Medical Instruments, Iowa City, Iowa) was inserted percutaneously into the peroneal nerve, located posterior to the fibular head. A reference electrode was placed subcutaneously in close proximity. Stimuli were delivered through the recording electrode with positioning such that muscle twitches in the peroneal nerve distribution were obtained at <0.6 V. Further careful manipulation of the electrode with afferent testing ensured an optimal site for recording postganglionic sympathetic nerve activity. Raw action potentials were amplified (90 000 to 99 000 times), filtered (700-to 2000-Hz bandwidth), and integrated by use of the 662C-3 Nerve Traffic Analysis System (Bioengineering Department, University of Iowa) to obtain a mean voltage neurogram. Pulse synchronicity and low signal-to-noise ratio confirmed burst activity as being of muscle sympathetic efferent origin. The mean voltage neurogram was recorded on a Gould 2800 multichannel recorder for subsequent manual analysis of burst frequency (expressed as bursts per minute and bursts per 100 beats). Observations in the control subjects were performed at only one time period after 30 minutes of rest in the supine position. In the transplant recipients, recordings were performed before their usual oral dose of cyclosporine (after 30 minutes of supine rest) and at 30-minute intervals after dosing for 90 minutes. In three transplant recipients, recordings were continued for 120 minutes.
Forearm blood flow and cardiac output. Eight cardiac transplant recipients were studied under this protocol (in six of these patients, microneurography was also performed at the same time, as described above). Blood pressure, forearm blood flow, and microneurographic measurements were recorded after a period of 30 minutes of rest, and after cyclosporine administration they were recorded at half-hour intervals for 2 hours. Cardiac output (as described below) and whole-blood cyclosporine levels were determined before and then at hourly intervals after cyclosporine dosing for 2 hours.
Blood pressure was measured noninvasively in these subjects by either a digital volume-clamp method (Finapress; Ohmehda, Denver, Colo) or an oscillometric cuff method (model 9300, Paramed, Calif). Heart rate was monitored electrocardiographically. The Biochemical assays. Blood samples for catecholamine assays were immediately transferred to ice-chilled tubes containing EGTA and reduced glutathione, then centrifuged at 40C. Plasma samples were then stored at -70'C until assay. Plasma concentrations of endogenous and radiolabeled norepinephrine and DHPG were determined by high-performance liquid chromatography with electrochemical detection as previously de- scribed. 20 The integration of a fraction collector allowed the separation of tritiated norepinephrine and its tritiated metabolite for subsequent counting by liquid scintillation spectroscopy. Plasma renin activity was measured by enzymatic generation of angiotensin I followed by radioimmunoassay of the generated angiotensin 1 
Hemodynamics
Mean arterial blood pressure in the cardiac transplant patients (recorded before cyclosporine dosing) was significantly higher than in age-matched controls (112±4 vs 87±4 mm Hg; P=.001). In cardiac transplant patients, the cardiac output before cyclosporine dosing was 3.7±0.4 L/min, and the total peripheral resistance was 31.3+6.1 mm Hg* L`-min-l. The acute administration of cyclosporine had no effect on mean arterial blood pressure (3±2.3 mm Hg, ±SED) over the 2-hour study period (Fig 1A) , despite an average increase in whole-blood cyclosporine levels of 133%, from a mean of 605 ,ug/L to 1411 ,ug/L (P<.001, Fig 1B) . In addition, cyclosporine therapy did not alter cardiac output during this period of observation (Fig 1C) . Renal blood flow was significantly lower in the heart transplant recipients compared with control subjects before acute cyclosporine dosing (680±88 vs 1285±58 mL/min; P<.001). In response to cyclosporine dosing, a progressive decline in renal blood flow was demonstrated, with a reduction of 37% at the 2-hour measurement (P<.001; Fig 2A) . In the three transplant patients not receiving cyclosporine, renal blood flow was unchanged over 2 hours of observation (7.0±18.6 mL/min, +SED). The change in renal blood flow in patients receiving cyclosporine was attributable to a progressive rise in renal vascular resistance, because mean arterial pressure was not altered over this period. In contrast, forearm blood flow progressively rose after the administration of cyclosporine (Fig 2B) , increasing from 1.7±0.3 to 3.1±0.5 mL min`-* 100 mL tissue-' (P<.001), reflecting a 42% reduction in forearm vascular resistance. Total peripheral resistance, however, was unchanged (Fig 2C) .
Norepinephrine Kinetics
The concentration of norepinephrine in arterial plasma was similar in the control subjects and heart transplant recipients studied 2 hours after cyclosporine dosing (1104±163 vs 1468±223 pmol/L). The rate of total norepinephrine spillover into the circulation was also similar in control subjects and transplant patients (2618±313 vs 3070±538 pmol/min). The whole-body clearance rate for norepinephrine was also similar for healthy control subjects and the transplant recipients (2.44±0.10 vs 2.35±0.20 L/min), as was the spillover of norepinephrine from the kidneys into the renal circulation (573±95 pmol/min in healthy subjects vs 579±124 pmol/min in transplant recipients). In response to acute oral administration of cyclosporine, neither the wholebody nor renal norepinephrine spillover rates were observed to change (Fig 3) . In the three time-control subjects not receiving cyclosporine acutely, whole-body and renal norepinephrine also remained unchanged after 2 hours of observation.
The arterial plasma renin activity was 0.92±0.3 g * L`-'* h' in the transplant recipients, which did not differ significantly from that of the control subjects (0.75 ±0.3 ,g * L-1 h'). The renal release rate of renin was also not significantly different for control subjects and transplant recipients.
To test for effects of cyclosporine on the reuptake or intraneuronal metabolism of norepinephrine, the fractional extraction of tritiated norepinephrine across the renal circulation and the production of 3H-DHPG were determined. The fractional extraction of norepinephrine was 53±3% in transplant recipients 2 hours after cyclosporine and 56±4% in control subjects (P=NS). Additionally, the fractional extraction was not affected acutely by cyclosporine administration. The arterial concentration of tritiated DHPG was also similar between control subjects and transplant recipients (31.2±3.9 vs 31.9±2.1 dpm/ mL). The renal production of 3H-DHPG was also similar in the two groups (control subjects vs transplant patients, 8200±6120 vs 8170±2810 dpm/min).
Microneurography
Microneurographic recordings (Fig 4) of sympathetic nerve activity in the peroneal nerve demonstrated an average burst frequency of 30.6±7.6 bursts per minute (37.9±10.1 bursts per 100 beats) immediately before cyclosporine dosing in the transplant recipients. Healthy control subjects had an average burst frequency of 25.8±1.6 bursts per minute (41.3±2.3 bursts per 100 beats), which did not differ significantly from that observed in the transplant recipients. After cyclosporine administration in the transplant patients, sympathetic burst activity (followed for up to 120 minutes) remained unchanged (Fig 5) , although only three subjects were studied at the final time point because of instability of the recording site in the other three subjects.
Discussion
Our study is in agreement with the widely recognized observation that cardiac transplant recipients treated with cyclosporine have a higher blood pressure than age-matched control subjects. The elevation of blood pressure was associated with a normal or mildly reduced cardiac output and an elevation of total peripheral resistance, similar to the findings reported by Greenberg et al. 23 Furthermore, we found that transplant patients receiving cyclosporine had reduced renal blood flow compared with age-matched control subjects. The SNA is quantified as bursts per minute (b/min) and bursts per 100 heart beats (bIlOOHB).
acute elevation in whole-blood cyclosporine levels that follows oral administration was associated with an additional decline in renal blood flow, by 37% at 2 hours after dose, whereas in the three transplant recipients acting as time controls, renal blood flow was unchanged over the 2-hour observation period. Cyclosporine therapy has generally been shown to reduce both glomerular filtration rate and renal plasma flow,24'25 with a concomitant fall in the fractional excretion of sodium and an expansion of the extracellular fluid volume. The mechanism responsible for this effect of cyclosporine has been the subject of much controversy. A role for enhanced sensitivity to a variety of vasoconstrictors, including norepinephrine, angiotensin II, and arginine vasopressin, has been suggested, in addition to increased production of thromboxane A2 and endothelin. [26] [27] [28] In humans, cyclosporine has been shown to impair endothelium-mediated vasodilation in subcutaneous resistance arteries,29 although what role these vessels might play in the determination of peripheral vascular resistance in vivo is unclear. In a recent report by Carrier et al,30 however, the renovascular effects of cyclosporine were not attenuated by a-adrenergic blockade or thromboxane receptor antagonism, and the stimulated release of endothelium-derived relaxing factor (by infusion of acetylcholine directly into the renal artery) was preserved. Alternatively, a neural basis for cyclosporine-mediated renal vasoconstriction has been proposed on the basis of observations of increased renal catecholamine concentrations31 and renal sympathetic nerve activity.8 This neural hypothesis, however, fails to explain the observations that renal sympathectomy does not ameliorate the renal vasoconstrictor effect of cyclosporine either in an experimental model30 or during the early phase after renal transplantation32 when the renal allograft is denervated.
Our results using two complementary techniques for assessing the activity of the sympathetic nervous system (norepinephrine kinetics and microneurography) do not support the hypothesis that cyclosporine therapy causes sympathoexcitation in humans, either during chronic therapy or in response to acute elevations of blood levels of cyclosporine in the postdosing period. Arterial concentrations of norepinephrine and the rate of norepinephrine spillover into plasma in cyclosporinetreated cardiac transplant recipients were similar to those of age-matched controls. Furthermore, the renal vasoconstriction associated with cyclosporine therapy was not associated with elevated renal norepinephrine spillover. Previously, this methodology has shown that renal norepinephrine spillover measurements faithfully reflect renal sympathetic nerve firing in animals over a range of renal blood flows.33 In humans, total norepinephrine spillover measurements are sufficiently sensitive to detect pharmacological suppression of sympathetic nerve neurotransmitter release by clonidine and the ganglionic blocking drug arfonad. 34 Similarly, reduction in total norepinephrine spillover is seen with the sympathetic withdrawal accompanying fainting reactions and physical conditioning through exercise training and with the sympathetic nerve failure of idiopathic training, whereas increased spillover rates are associated with sodium restriction, heart failure, and cirrhosis.34 Thus, it is unlikely that in cyclosporine-treated patients our calculated renal spillover rates of norepinephrine were spuriously low in the face of low renal blood flow.
In testing for possible separate effects of cyclosporine on the sympathetic neuroeffector junction (including the neuronal reuptake of norepinephrine), we found that the fractional extraction of tracer norepinephrine across the kidneys was not altered by cyclosporine. This finding reinforces our conclusion that a reduction in renal blood flow to the extent observed is unlikely to have confounded our measurements of renal norepinephrine spillover by a mechanism such as a reduction in flow-dependent washout.35 In addition, the arterial concentration of 3H-DHPG formed by intraneuronal metabolism of norepinephrine after neuronal uptake was normal. This implies that the disposition of neuronally released norepinephrine is not affected by cyclosporine.
The finding of reduced renal blood flow in the cardiac transplant recipient group before cyclosporine dosing (and presumably at trough blood levels) could be explained by a number of mechanisms. First, the trough levels (605 ,ug/L) may still produce a renal vasoconstrictor effect alone. In addition, a chronic nephrotoxic effect of cyclosporine and the potential effect of severe heart failure (before transplantation) on renal function may play an additional role.
Cyclosporine-induced hypertension in humans has been characteristically associated with normal or low renin levels.5,36 This contrasts with the finding in young essential hypertensive subjects (without transplants) who are commonly noted to have high plasma renin activity and renal renin release rates. 37 This group of hypertensive patients has shown increased sympathetic activity measured by either whole-body and renal norepinephrine spillover or microneurography.38 Increased plasma renin activity in this group is explained in part by the fact that renin release from the kidney is under sympathetic control.39 In keeping with our finding that whole-body and renal spillover rates of norepinephrine in our transplant patient group were similar to those of the control group, we also noted that plasma renin activity (and renal release) did not differ significantly from healthy control subjects. If cyclosporine were to cause hypertension via sympathoexcitation, elevation of plasma renin activity would be expected.
Recently, Scherrer et a14 used microneurographic techniques to record sympathetic nerve activity in the peroneal nerve in cardiac transplant recipients, some of whom were not receiving cyclosporine as a part of their immunosuppressive regimen. In their study, patients treated with cyclosporine had higher rates of sympathetic nerve firing, suggesting that cyclosporine-induced hypertension is neurogenic, caused by sympathetic activation. There is no immediate explanation for the discrepancy between these findings and the present study. In the study of Scherrer et al, some patients were receiving clonidine and/or diuretics, and it is therefore possible that withdrawal of these drugs may have contributed to the sympathetic activation noted. Our measurements of sympathetic nerve activity in the peroneal nerve demonstrated no differences between transplant patients and healthy normal subjects. In the present study, the healthy control subjects were slightly younger than transplant recipients, but since sympathetic nerve activity increases with age,40 the findings of similar levels of nerve firing and norepinephrine spillover rates further strengthens our conclusion that cyclosporine does not produce sympathetic activation. We were unable to include a group of transplant recipients not treated with cyclosporine (as included by Scherrer et al), however, since our present policy on immunosuppressive therapy is to use cyclosporine in all transplant recipients. In Scherrer's study, this group of patients did not display significantly different nerve firing rates from those of their control subjects.
Although chronic cyclosporine therapy is associated with a significant incidence of hypertension, the acute effects of cyclosporine remain more variable. In animals, acute cyclosporine administration in large bolus doses (in a manner differing from the usual clinical mode of administration) has been associated with either an increase,3 decrease,41 or no change in arterial blood pressure. 26 Weir et a124 examined the effect of subacute administration of intravenous cyclosporine in normal volunteers and found that blood pressure was unaltered, but a reduction in glomerular filtration rate was detected. In the present study, we observed that chronic cyclosporine therapy was associated with reduced renal blood flow and elevated blood pressure. After the oral administration of cyclosporine in this patient group, renal blood flow fell further, but the blood pressure was unchanged. Differences in renin production are also apparent in animal studies of acute cyclosporine administration, which has been characterized by high renin activity,42 compared with chronic cyclosporine therapy in humans, which is associated with normal or low plasma renin activity.5 Because of these contrasting findings and the suggestion that interspecies differences in response to cyclosporine may exist,2 care must be taken in extrapolating data derived from animal studies to the human form of cyclosporine-induced hypertension.
The administration of cyclosporine was associated with a progressive rise in forearm blood flow during our study, which was not associated with a change in mean arterial blood pressure or cardiac output. These observations are in keeping with observations in rats that the vasoconstrictive effects of cyclosporine are largely confined to the renal circulation.26 Although in the present study, a time-control study of forearm blood flow was not performed, previous work from this laboratory43 has shown that forearm blood flow remains unchanged during a controlled observation period of 2 hours. Therefore, it is possible that the progressive reduction in forearm vascular resistance observed after cyclosporine dosing represents central baroreflex-mediated vasodilation, although a direct vasodilator effect on the circulation of skeletal muscle could not be excluded.
Direct recording of muscle sympathetic nerve activity in the upper limb was not performed, however, and since significant differences in nerve activity may exist in the upper and lower limb,44 it is not possible to draw firm conclusions about the mechanism of the forearm vasodilation observed in this study.
In conclusion, we observed that renal, skeletal muscle, and total sympathetic nervous system activity was normal in relation to peak and trough levels of cyclosporine, according to dosing regimens used in routine clinical practice. The use of the immunosuppressive agent was associated with nonneural renal vasoconstriction, which appeared to follow a time course related to rising blood levels of the drug. The hypertension associated with cyclosporine therapy is a chronic manifestation of its use, since acute fluctuations in cyclosporine levels were not associated with blood pressure changes after dosing. The practical implication of the findings arising from this study is that cyclosporine-induced hypertension does not appear to be adrenergically driven, at least in its chronic clinical form, and is characterized by renal vasoconstriction. Therefore, it may be appropriate to treat this form of hypertension with nonantiadrenergic antihypertensive medications. Furthermore, comparative studies of calcium antagonists (notably nifedipine) and prazosin45 have shown that the former has protective actions against the nephrotoxic effects of cyclosporine in addition to effective antihypertensive action. Despite the adverse hypertensive and nephrotoxic actions, cyclosporine remains at present a valuable immunosuppressive agent, with valuable effects on allograft and patient survival after transplantation.
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